In their first public appearance since the drug’s debut, the marketing stewards behind GLP-1 obesity medicine Wegovy looked back at a launch for the ages.
“I think there’s this misperception that, ‘Oh, the people at Novo Nordisk must be dancing in the halls and celebrating every single day,’” said Tejal Vishalpura, SVP, commercial strategy and marketing for the Danish drugmaker. “Actually, we hadn’t stopped to even reflect on our journey because we are so heads-down every single day.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,